RBC Capital Initiates Coverage On Viridian Therapeutics with Outperform Rating, Announces Price Target of $44
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with an Outperform rating and a price target of $44.
May 30, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital initiates coverage on Viridian Therapeutics with an Outperform rating and a price target of $44.
RBC Capital's initiation of coverage on Viridian Therapeutics with an Outperform rating and a price target of $44 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100